CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID). The purpose of this evaluation is to determine the feasibility, acceptability and effectiveness of this treatment. It is hypothesised that this treatment will be feasible and acceptable to clinicians, carers and patients and will be effective in reducing symptoms of ARFID for patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Feasibility
Timeframe: Upon conclusion of the study (week 18-30)
Acceptability: CTS
Timeframe: The CTS will be completed upon conclusion of the study (week 18-30)
Acceptability: CSQ
Timeframe: The CSQ will be completed upon conclusion of the study (week 18-30)
Acceptability: Adverse events
Timeframe: Adverse events will be collected weekly between baseline and the conclusion of the study (week 18-30)
Acceptability: Qualitative Feedback
Timeframe: Qualitative feedback will be collected at the conclusion of the study (end of stage 4, week 20-30)
Effectiveness: PARDI-AR-Q
Timeframe: The PARDI-AR-Q will be assessed at baseline, and at the conclusion of stages 2 (week 4-6) and 3 (week 18-28) and at conclusion of the study (week 18-30)
Effectiveness: FNS
Timeframe: The FNS will be assessed at baseline and weekly and upon conclusion of the study (week 18-30)